In this edition:
DUO-O: triplet therapy in advanced ovarian cancer
MIRASOL: mirvetuximab soravtansine in high FRα-expressing PROC
Ofranergene obadenovec (VB-111) + paclitaxel in PROC
Luveltamab tazevibulin in recurrent ovarian cancer
OVHIPEC-1: 10-year follow-up of HIPEC + CRS in ovarian cancer
CHIPOR: HIPEC in platinum-sensitive relapsed epithelial ovarian cancer
Palbociclib + letrozole in recurrent advanced/metastatic ER+/PR+ ovarian cancer
Elderly ovarian cancer care compliance in Australia
Avutometinib + defactinib in recurrent LGSOC
Azenosertib + chemotherapy in platinum-resistant/refractory epithelial ovarian/peritoneal/fallopian tube cancer
Please login below to download this issue (PDF)